296 related articles for article (PubMed ID: 25069786)
1. Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study.
Riba J; McIlhenny EH; Bouso JC; Barker SA
Drug Test Anal; 2015 May; 7(5):401-6. PubMed ID: 25069786
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
[TBL] [Abstract][Full Text] [Related]
3. Dimethyltryptamine (DMT): subjective effects and patterns of use among Australian recreational users.
Cakic V; Potkonyak J; Marshall A
Drug Alcohol Depend; 2010 Sep; 111(1-2):30-7. PubMed ID: 20570058
[TBL] [Abstract][Full Text] [Related]
4. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics.
Riba J; Valle M; Urbano G; Yritia M; Morte A; Barbanoj MJ
J Pharmacol Exp Ther; 2003 Jul; 306(1):73-83. PubMed ID: 12660312
[TBL] [Abstract][Full Text] [Related]
5. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.
Dos Santos RG; Valle M; Bouso JC; Nomdedéu JF; Rodríguez-Espinosa J; McIlhenny EH; Barker SA; Barbanoj MJ; Riba J
J Clin Psychopharmacol; 2011 Dec; 31(6):717-26. PubMed ID: 22005052
[TBL] [Abstract][Full Text] [Related]
6. Liquid chromatography-tandem mass spectrometry method for the bioanalysis of N,N-dimethyltryptamine (DMT) and its metabolites DMT-N-oxide and indole-3-acetic acid in human plasma.
Luethi D; Kolaczynska KE; Vogt SB; Ley L; Erne L; Liechti ME; Duthaler U
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Dec; 1213():123534. PubMed ID: 36434963
[TBL] [Abstract][Full Text] [Related]
7. Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids
Brito-da-Costa AM; Dias-da-Silva D; Gomes NGM; Dinis-Oliveira RJ; Madureira-Carvalho Á
Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33114119
[TBL] [Abstract][Full Text] [Related]
8. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.
Halberstadt AL
Pharmacol Biochem Behav; 2016 Apr; 143():1-10. PubMed ID: 26780349
[TBL] [Abstract][Full Text] [Related]
9. Pharmahuasca: human pharmacology of oral DMT plus harmine.
Ott J
J Psychoactive Drugs; 1999; 31(2):171-7. PubMed ID: 10438001
[TBL] [Abstract][Full Text] [Related]
10. Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine.
McIlhenny EH; Riba J; Barbanoj MJ; Strassman R; Barker SA
Biomed Chromatogr; 2011 Sep; 25(9):970-84. PubMed ID: 21058415
[TBL] [Abstract][Full Text] [Related]
11. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca.
McKenna DJ; Towers GH; Abbott F
J Ethnopharmacol; 1984 Apr; 10(2):195-223. PubMed ID: 6587171
[TBL] [Abstract][Full Text] [Related]
12. Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT.
Barker SA
Psychopharmacology (Berl); 2022 Jun; 239(6):1749-1763. PubMed ID: 35064294
[TBL] [Abstract][Full Text] [Related]
13. Kinetic profile of N,N-dimethyltryptamine and β-carbolines in saliva and serum after oral administration of ayahuasca in a religious context.
Lanaro R; Mello SM; da Cunha KF; Silveira G; Corrêa-Neto NF; Hyslop S; Cabrices OG; Costa JL; Linardi A
Drug Test Anal; 2021 Mar; 13(3):664-678. PubMed ID: 33119972
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans.
Valle M; Maqueda AE; Rabella M; Rodríguez-Pujadas A; Antonijoan RM; Romero S; Alonso JF; Mañanas MÀ; Barker S; Friedlander P; Feilding A; Riba J
Eur Neuropsychopharmacol; 2016 Jul; 26(7):1161-75. PubMed ID: 27039035
[TBL] [Abstract][Full Text] [Related]
15. Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT).
Witowski CG; Hess MR; Jones NT; Pellitteri Hahn MC; Razidlo J; Bhavsar R; Beer C; Gonzalez-Velazquez N; Scarlett CO; Wenthur CJ; von Salm JL
Eur J Pharm Sci; 2024 Aug; 199():106803. PubMed ID: 38788435
[TBL] [Abstract][Full Text] [Related]
16. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).
Cameron LP; Olson DE
ACS Chem Neurosci; 2018 Oct; 9(10):2344-2357. PubMed ID: 30036036
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of ayahuasca administered in two repeated doses.
Dos Santos RG; Grasa E; Valle M; Ballester MR; Bouso JC; Nomdedéu JF; Homs R; Barbanoj MJ; Riba J
Psychopharmacology (Berl); 2012 Feb; 219(4):1039-53. PubMed ID: 21842159
[TBL] [Abstract][Full Text] [Related]
18. Syrian rue seeds interacted with acacia tree bark in an herbal stew resulted in N,N-dimethyltryptamine poisoning.
Liu CH; Chu WL; Liao SC; Yang CC; Lin CC
Clin Toxicol (Phila); 2019 Oct; 57(10):867-869. PubMed ID: 30831037
[No Abstract] [Full Text] [Related]
19. A pilot study of cerebral metabolism and serotonin 5-HT
Egger K; Gudmundsen F; Jessen NS; Baun C; Poetzsch SN; Shalgunov V; Herth MM; Quednow BB; Martin-Soelch C; Dornbierer D; Scheidegger M; Cumming P; Palner M
Front Pharmacol; 2023; 14():1140656. PubMed ID: 37841918
[No Abstract] [Full Text] [Related]
20. A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010.
Barker SA; McIlhenny EH; Strassman R
Drug Test Anal; 2012; 4(7-8):617-35. PubMed ID: 22371425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
